藥明康德瑞士早餐會：新藥研發(fā)的“協(xié)同加速度”｜Bilingual

當(dāng)今醫(yī)療健康領(lǐng)域面臨的核心挑戰(zhàn)之一，并非科學(xué)創(chuàng)新的匱乏。從許多方面來看，情況恰恰相反。生物醫(yī)藥科學(xué)技術(shù)正以前所未有的速度向前推進(jìn)，新的治療模式正打開曾經(jīng)遙不可及的可能性之門，世界各地的研究人員不斷拓展著創(chuàng)新科學(xué)造福病患的邊界。

然而，更嚴(yán)峻的挑戰(zhàn)在于，如何將這些進(jìn)步，以患者急需的速度和質(zhì)量，轉(zhuǎn)化為切實可及的治療方案。

▲從左至右依次為：DebiopharmResearch & Manufacturing首席執(zhí)行官Cédric Sager博士，拜耳制藥瑞士區(qū)負(fù)責(zé)人Thorsten Hein先生，F(xiàn)oRx Therapeutics首席科學(xué)官Frank Zenke博士，瑞士生物技術(shù)協(xié)會首席執(zhí)行官Michael Altorfer博士，藥明康德副總裁暨會議主持人蔡輝博士

正是這個命題，貫穿了在巴塞爾舉行的WuXi Executive Breakfast的整場討論。該活動在瑞士生物技術(shù)日期間舉辦，吸引了來自生物技術(shù)、制藥、風(fēng)險投資以及更廣泛的醫(yī)療健康生態(tài)系統(tǒng)的行業(yè)領(lǐng)袖。

討論中，演講者從不同的視角，回歸到一個相似的結(jié)論：僅憑科學(xué)創(chuàng)新已不足以應(yīng)對當(dāng)下挑戰(zhàn)。產(chǎn)業(yè)進(jìn)步越來越取決于藥物發(fā)現(xiàn)、開發(fā)、生產(chǎn)以及全球?qū)I(yè)能力能否形成一體化系統(tǒng)，并實現(xiàn)高效協(xié)同。

這場討論，從多個維度呼應(yīng)了今年瑞士生物技術(shù)日主題所倡導(dǎo)的精神——國際合作的力量。

▲從左至右依次為：藥明康德副總裁Vikalp Mohan先生、副總裁蔡輝博士、副總裁Dave Madge博士、藥明康德旗下Crelux公司負(fù)責(zé)人Thomas Meins博士

速度至關(guān)重要：縮短患者等待的時間

對于新興的生物技術(shù)公司而言，時間是最稀缺的資源之一。

FoRx Therapeutics最近剛宣布完成5000萬美元的A輪融資。其首席科學(xué)官Frank Zenke博士分享了該公司如何在約18個月內(nèi)，將一款DNA修復(fù)小分子抑制劑從分析方法開發(fā)推進(jìn)至IND獲批。他表示：“在藥明康德的幫助下，我們成功開發(fā)了臨床前檢測方法，完成了IND準(zhǔn)備工作，并推進(jìn)了CMC相關(guān)工作。”在他看來，科學(xué)之外，項目能否快速推進(jìn)，取決于專業(yè)知識和執(zhí)行能力能否圍繞共同目標(biāo)有效協(xié)同。

與此同時，創(chuàng)新本身的復(fù)雜度也在持續(xù)攀升。

Debiopharm Research & Manufacturing的首席執(zhí)行官Cédric Sager博士指出，抗體偶聯(lián)藥物（ADC）和放射性配體療法等新興治療模式正在重塑行業(yè)的開發(fā)需求。這些療法越來越依賴于高度專業(yè)化的能力，涵蓋連接子化學(xué)、多肽技術(shù)、先進(jìn)生產(chǎn)以及協(xié)調(diào)的供應(yīng)體系。“我們在某些領(lǐng)域是專家，”他說，“但在其他領(lǐng)域，我們需要伙伴與我們并肩前行。”

科學(xué)研究越是邁向新的前沿，研發(fā)生態(tài)系統(tǒng)就越必須隨之演進(jìn)。

協(xié)作：決定創(chuàng)新速度的關(guān)鍵變量

拜耳制藥瑞士區(qū)負(fù)責(zé)人Thorsten Hein先生強調(diào)了在產(chǎn)業(yè)鏈上下游，以及不同國家和地區(qū)之間建立更牢固橋梁的重要性，以推動創(chuàng)新更高效、更可靠地造福患者。

他指出，患者需求和醫(yī)療創(chuàng)新本身都具有全球性，關(guān)鍵在于搭建連接歐洲、亞洲和北美之間的橋梁，使合作能夠更緊密、更高效地展開。

這種互聯(lián)互通的精神，也是瑞士生物技術(shù)日的核心氛圍。瑞士生物技術(shù)協(xié)會首席執(zhí)行官Michael Altorfer博士強調(diào)，構(gòu)建一個能夠讓全球生物科技行業(yè)自然建立信任與協(xié)作的生態(tài)，至關(guān)重要。他指出，像瑞士生物技術(shù)日這樣匯聚3600多位參會者，其中50%來自瑞士以外地區(qū)的大會，恰恰為創(chuàng)新者、科學(xué)家、投資者和合作伙伴提供了寶貴的連接機會，最終有助于加速將治療進(jìn)展帶給患者。

在現(xiàn)代藥物研發(fā)中，協(xié)作已不再僅僅是創(chuàng)新的輔助手段。它正日益成為使創(chuàng)新得以實現(xiàn)的基礎(chǔ)設(shè)施。

一體化：正在成為加速創(chuàng)新的重要推動力

隨著研發(fā)項目日趨復(fù)雜——涵蓋下一代小分子、多肽、寡核苷酸、偶聯(lián)物以及其他新興治療模式——討論自然轉(zhuǎn)向了一體化執(zhí)行的重要性。

在此背景下，藥明康德的一體化、端到端的CRDMO平臺被多次提及。該平臺打通了從藥物發(fā)現(xiàn)、開發(fā)至商業(yè)化生產(chǎn)的全鏈條能力，可有效解決傳統(tǒng)研發(fā)中因環(huán)節(jié)分散、割裂而導(dǎo)致的低效問題，加速客戶的新藥項目從構(gòu)想到落地的轉(zhuǎn)化進(jìn)程。就在活動舉辦前三天，美國FDA批準(zhǔn)了首款異雙功能性蛋白降解劑，為靶向蛋白降解領(lǐng)域帶來重要里程碑。 藥明康德依托CRDMO一體化平臺整合化學(xué)、生物學(xué)和測試等能力，助力臨床前候選化合物在13個月內(nèi)的快速推進(jìn)和交付，而行業(yè)常規(guī)周期約為24個月。藥明康德還為這一項目提供了從快速開發(fā)、放大生產(chǎn)到用于臨床試驗的GMP物料生產(chǎn)的端到端支持。

討論也進(jìn)一步詮釋了藥明康德持續(xù)拓展全球能力和區(qū)域布局的意義。為滿足全球客戶對研發(fā)效率、產(chǎn)能彈性和本地化支持的需求，藥明康德持續(xù)加快能力與產(chǎn)能建設(shè)。在歐洲，藥明康德位于德國慕尼黑和瑞士庫威的基地持續(xù)為歐洲及全球客戶提供從早期研發(fā)到高質(zhì)量制劑生產(chǎn)的支持。去年，藥明康德宣布將在慕尼黑設(shè)立歐洲總部，以更好地支持歐洲客戶。更貼近歐洲、北美和亞洲的合作伙伴，意味著更及時的溝通、更順暢的協(xié)作和更高效的項目推進(jìn)，從而為全球創(chuàng)新提供更堅實的支持。

一個愈發(fā)清晰的趨勢

瑞士生物技術(shù)日作為極具代表性且高度國際化的活動，反映了一個日益增長的共識：從科學(xué)發(fā)現(xiàn)到造福患者的連接路徑，正變得更加互聯(lián)、多學(xué)科和全球化。醫(yī)療健康的進(jìn)步正越來越成為一項集體事業(yè)，需要集體的努力和協(xié)同。

而這，或許正是這個早晨最值得銘記的一課：當(dāng)今藥物研發(fā)領(lǐng)域最重要的生態(tài)創(chuàng)新，或許是整個行業(yè)如何更有效地攜手合作——將有望改變生命的科學(xué)成果，以更高效、更可靠的方式，帶給全球患者。

The Most Important Innovation in Drug R&D May Be How the Industry Works Together

Reflections from the WuXi Executive Breakfast at Swiss Biotech Day

One of the defining challenges in healthcare today is not a lack of scientific ideas. In many ways, the opposite is true. The greater challenge now is translating those advances into therapies with the speed and quality patients urgently need.

That theme shaped the discussions at theWuXi Executive Breakfastin Basel, held alongside Swiss Biotech Day and attended by nearly 100 leaders from biotech, pharma, venture capital, and the broader healthcare ecosystem.

▲From left to right: Dr. Cédric Sager, CEO ofDebiopharmResearch & Manufacturing; Mr.Thorsten Hein, Country Division Head of Bayer Pharma Switzerland;Dr. Frank Zenke, CSO of FoRx Therapeutics; Dr. Michael Altorfer, CEO of the Swiss Biotech Association; Dr. Hui Cai, VP of WuXi AppTec and event moderator

Throughout the morning, speakers returned — often from very different perspectives — to a remarkably similar conclusion:scientific innovation alone is no longer enough. Increasingly, progress depends on how effectively discovery, development, manufacturing, and global expertise can work together as an integrated system.

In many ways, the conversation reflected the broader spirit of this year’s Swiss Biotech Day theme —The Power of International Collaboration.

▲From left to right: Mr.Vikalp Mohan,Vice President at WuXi Chemistry; Dr. Hui Cai, Vice President, WuXi AppTec; Dr.Dave Madge,Vice President at WuXi Biology; Dr. Thomas Meins, Managing Director at Crelux, a WuXi AppTec company

Speed Matters Because Patients Are Waiting

For emerging biotech companies, time remains one of the most precious resources.

Dr. Frank Zenke, CSO of FoRx Therapeutics based in Switzerland, which recently announced a $50 million Series A financing, shared how the company advanced a small molecule inhibitor from assay development into an IND-approved program and Phase 1 trial within roughly 18 months. “We successfully developed a preclinical assay, prepared the IND, and worked on the CMC with the help of WuXi AppTec,” he said. For him,the ability to move quickly depends on how effectively expertise and execution capabilities can align around a common goal.

Innovation itself is also becoming more sophisticated.

Dr. Cédric Sager, CEO of Debiopharm Research & Manufacturing, described how emerging modalities such as ADCs and radioligand therapies are reshaping development requirements across the industry. These therapies increasingly rely on highly specialized capabilities spanning linker chemistry, peptide technologies, advanced manufacturing, and coordinated supply systems.

“We are experts in some areas,” he noted, “but we need others to help us move forward.”As science advances into new frontiers, development ecosystems must evolve alongside it.

Collaboration Is Becoming Infrastructure

Mr. Thorsten Hein, Country Division Head of Bayer Pharma Switzerland, emphasized the importance of building stronger bridges across the upstream and downstream parts of the industry value chain, as well as across countries and regions, to help innovation reach patients efficiently and reliably.

With both patient needs and healthcare innovation becoming inherently global, he said, “It’s about building bridges between Europe, Asia, and the U.S., so we can work together more closely and effectively.”

That spirit of connectivity was central to the atmosphere of Swiss Biotech Day itself.

Dr. Michael Altorfer, CEO of the Swiss Biotech Association, reflected on the importance of creating environments where trust and relationships can develop naturally across the global biotech community. “Our relationship with WuXi dates back many, many years,” he said. Conferences like Swiss Biotech Day with 3600 delegates and 50% from outside Switzerland, he noted, help innovators, scientists, investors, and partners connect in ways that can ultimately accelerate progress for patients.

In modern drug development, collaboration is no longer simply supportive to innovation. Increasingly, it is becoming part of the infrastructure that makes innovation possible.

Integration as an Enabler of Innovation

As scientific programs become more complex — spanning next-generation small molecules, peptides, oligonucleotides, conjugates, and other emerging modalities — many conversations naturally turned toward the importance of integrated execution.

Within that context, WuXi AppTec’s integrated CRDMO platform was discussed as one approach designed to help innovators move more seamlessly across traditionally fragmented stages of development by connecting discovery, development, and manufacturing through coordinated teams and technology platforms.

Examples shared during the breakfast illustratedhow integrated approaches can help reduce operational complexity while supporting speed, quality, and scientific rigorsimultaneously— from accelerating synthesis and formulation timelines for complex molecules to supporting the first FDA-approved Proteolysis-Targeting Chiemera drug – helping a client advancing a preclinical candidate within 13 months versus the industry average of 24 months with integrated support from chemistry, biology, testing, scale-up, and GMP clinical material manufacturing. WuXi AppTec’s CRDMO platform provided end-to-end support for this program, from rapid development and scale-up to the manufacturing of GMP materials for clinical trials.

The discussion also further underscored the significance of WuXi AppTec’s continued expansion of its global capabilities and regional footprint. To meet global customers’ needs for R&D efficiency, capacity flexibility, and localized support, WuXi AppTec is accelerating the build-out of its capabilities and capacity.

In Europe, WuXi AppTec's sites in Munich, Germany and in Couvet, Switzerland continue to support customers in Europe and around the world, from early-stage R&D to high-quality drug product manufacturing.

Last year, WuXi AppTec announced plans to establish its European headquarters in Munich to better support customers across Europe. Being closer to partners in Europe, North America, and Asia means more timely communication, smoother collaboration, and more efficient project execution, providing stronger support for global innovation.

What the Breakfast Ultimately Reflected

By the end of the session, one thing had become increasingly clear:the future of drug development will not be defined solely by scientific breakthroughs themselves, but by how effectively the global R&D ecosystem can coordinate around those breakthroughs.

Swiss Biotech Day’s largest and most international gathering to date reflected the growing recognition thathealthcare progress is increasingly a collective effort.

And perhaps that was the most important insight from the morning:

The most important innovation in drug R&D today may be how effectively the industry learns to work together to bring innovation to patients around the world.

免責(zé)聲明：本文僅作信息交流之目的，文中觀點不代 表藥 明康德立場，亦不代 表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請在「藥明康德」微信公眾號回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。